Oncotarget

Research Papers:

Epidermal growth factor receptor (EGFR) mutations in non-small cell lung cancer (NSCLC) of Yunnan in southwestern China

Yongchun Zhou, Yanlong Yang, Chenggang Yang, Yunlan Chen, Changshao Yang, Yaxi Du, Guangqiang Zhao, Yinjin Guo, Lianhua Ye and Yunchao Huang _

PDF  |  HTML  |  Supplementary Files  |  How to cite

Oncotarget. 2017; 8:15023-15033. https://doi.org/10.18632/oncotarget.14706

Metrics: PDF 2313 views  |   HTML 4536 views  |   ?  


Abstract

Yongchun Zhou1,*, Yanlong Yang2,*, Chenggang Yang3,*, Yunlan Chen4, Changshao Yang5, Yaxi Du5, Guangqiang Zhao2,Yinjin Guo5, Lianhua Ye2, Yunchao Huang1,2

1Tumor Research Institute of Yunnan Province, The Third Affiliated Hospital of Kunming Medical University (Yunnan Tumor Hospital), Kunming, 650118, PR China

2Department of Thoracic Surgery I, The Third Affiliated Hospital of Kunming Medical University (Yunnan Tumor Hospital), Kunming, 650118, PR China

3Department of Pathology, The Third Affiliated Hospital of Kunming Medical University (Yunnan Tumor Hospital), Kunming, 650118, PR China

4Cadre Ward, The Third Affiliated Hospital of Kunming Medical University (Yunnan Tumor Hospital), Kunming, 650118, PR China

5Key Laboratory of Lung Cancer Research of Yunnan Province, The Third Affiliated Hospital of Kunming Medical University, Kunming, 650118, PR China

*These authors contributed equally to this work

Correspondence to:

Yunchao Huang, email: [email protected]

Keywords: non-small cell lung cancer, EGFR mutation, cftDNA, Yunnan, Xuanwei

Received: September 22, 2016     Accepted: November 18, 2016     Published: January 17, 2017

ABSTRACT

To investigate the Epidermal Growth Factor Receptor (EGFR) mutation status in non-small cell lung cancer (NSCLC) in Yunnan province in southwestern China, we detected EGFR mutation by Amplification Refractory Mutation System (ARMS) polymerase chain reaction (PCR) using DNA samples from 447 pathologically confirmed NSCLC specimens (175 tissue, 256 plasma and 16 cytologic samples). The relationship between EGFR mutations and demographic and clinical factors were further explored. Subgroup analyses according to sample type (tissue and plasma) and histological type (adenocarcinoma) were done. We found the mutation rate was 34.9% in overall patients (42.3%, 29.7%, and 37.5% for tissue, plasma, and cytologic samples respectively). We found female (p < 0.0001), no smoking (p = 0.001), adenocarcinoma (p < 0.0001), and tissue specimen (p = 0.026) were associated with higher EGFR mutation rate. The most common mutations were exon 19 deletions (40%) and L858R point (30%) mutation. Interestingly, NSCLC patients from Xuanwei harbored a strikingly divergent mutational pattern for EGFR when compared with non-Xuanwei patients (higher G719X, G719X+S768I mutations, but lower 19 deletion and L858R mutations). Generally, EGFR mutation rate and pattern in Yunnan province was in accord with other Asian populations. However, Xuanwei subgroup showed strikingly divergent EGFR mutation spectrum from other general population. Our analysis also indicated that cftDNA analysis for EGFR mutations detection was feasibility for the patients lacking sufficient tissue for molecular analyses.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 14706